已发表论文

同型半胱氨酸与早期帕金森病轻度认知障碍之间的非线性关系:一项横断面研究

 

Authors Ouyang Q , Xu L, Zhang Y, Huang L, Li L, Yu M

Received 23 January 2024

Accepted for publication 22 April 2024

Published 30 April 2024 Volume 2024:20 Pages 913—921

DOI https://doi.org/10.2147/NDT.S460938

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Yuping Ning

Qingrong Ouyang, Lei Xu, Yunwei Zhang, Luwen Huang, Linlin Li, Ming Yu

Department of Neurology, Suining Central Hospital, Suining, 629000, People’s Republic of China

Correspondence: Ming Yu, Tel +86 18008258574, Email ym1376@sns120.com

Background: Cognitive impairment, a prevalent non-motor symptom in advanced Parkinson’s disease (PD), has been associated with hyperhomocysteinemia, an important risk factor for PD progression and cognitive decline in PD. However, evidence regarding the association between homocysteine (Hcy) and cognitive function during early PD remains insufficient. Therefore, this study aims to examine the correlation between Hcy levels and cognitive function in the early stage of PD.
Methods: The study included 218 individuals in the early stages of PD who were consecutively admitted to the Suining Central Hospital Neurology Department. All the individuals completed the Parkinson’s Disease Cognitive Rating Scale (PD-CDR). The Unified Parkinson’s Disease Rating Scale part III (UPDRS-III) was employed for measuring the severity of motor symptoms, while the Hoehn-Yahr scale was used to measure the clinical symptom stage. Fasting venous blood samples were also drawn to measure the Hcy concentration, red blood cell folate, and vitamin B12.
Results: In this cross-sectional study, 47 (21.5%) patients with PD showed cognitive dysfunction. The serum Hcy levels were significantly higher in the cognitive impairment PD (PDCI) group compared with the cognitive normal PD group (P< 0.001). The Generalized Additive Model (GAM) analysis revealed a nonlinear relationship between Hcy and the risk of PDCI. Multiple logistic regression analyses demonstrated a positive relationship between elevated Hcy and the risk of PDCI in the fully adjusted model ([OR]:3.1, 95% CI, 1.1– 8.5, P=0.028). Segmented linear regression analysis showed that when Hcy levels were above 17.7 umol/l, the risk of PDCI increased by 1.6 times for every 1 unit elevated in Hcy (95% CI:1.1– 2.2, P=0.008).
Conclusion: This study revealed a nonlinear positive correlation between the risk of PDCI and elevated serum Hcy levels in early PD patients, suggesting hyperhomocysteinemia as one of the treatable factors for cognitive impairment in the early stages of PD.

Keywords: homocysteine, early Parkinson’s disease, cognitive impairment, relationship